Mergers & AcquisitionsMedium•13 October 2026•
1 min read
Alaunos Therapeutics Acquires Velaris and Raises $350M for Lung Research
Key Facts
1Alaunos Therapeutics announced the acquisition of Velaris Therapeutics.
2The company completed an oversubscribed $350 million private placement to fund pulmonary arterial hypertension research.
Alaunos Therapeutics announced the acquisition of Velaris Therapeutics in a strategic move to expand its research pipeline. According to a statement on GlobeNewswire, the company simultaneously completed an oversubscribed $350 million private placement to secure funding for its pulmonary arterial hypertension research.
The acquisition and capital injection are intended to position the company to deliver proof-of-concept datasets for its specialized treatments. In the equity markets, TCRT closed at $1.05 on October 12, 2026, reaching a day high of $1.05 and a low of $0.77 during that session.